NYSE - Delayed Quote USD

Edwards Lifesciences Corporation (EW)

88.61 +0.86 (+0.98%)
At close: 4:00 PM EDT
89.00 +0.39 (+0.44%)
After hours: 5:52 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Bernard J. Zovighian CEO & Director 2.27M -- 1968
Mr. Scott B. Ullem Corporate VP & CFO 1.35M 6.36M 1967
Mr. Donald E. Bobo Jr. Corporate Vice President of Strategy & Corporate Development 1.27M 2.68M 1962
Mr. Larry L. Wood Corporate VP and Group President of TAVR & Surgical Structural Heart 1.49M 2.13M 1966
Dr. Todd J. Brinton FACC, M.D. Corporate VP of Advanced Technology & Chief Scientific Officer -- -- --
Mark Wilterding Vice President of Investor Relations -- -- --
Mr. Arnold A. Pinkston Corporate VP & General Counsel -- -- 1959
Mr. Dirksen J. Lehman Corporate Vice President of Public Affairs -- -- --
Ms. Christine Z. McCauley Corporate Vice President of Human Resources -- -- 1965
Mr. Gary I. Sorsher Senior Vice President of Quality & Regulatory Compliance -- -- 1965

Edwards Lifesciences Corporation

One Edwards Way
Irvine, CA 92614
United States
949 250 2500 https://www.edwards.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
19,800

Description

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Corporate Governance

Edwards Lifesciences Corporation’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 4; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 25, 2024
Edwards Lifesciences Corporation Earnings Call

Related Tickers

BSX Boston Scientific Corporation
72.91
+5.68%
 
SYK Stryker Corporation
336.85
+0.58%
 
DXCM DexCom, Inc.
137.87
+2.89%
 
MDT Medtronic plc
80.38
-1.12%
 
ALGN Align Technology, Inc.
313.78
+0.61%
 
PODD Insulet Corporation
167.25
-0.01%
 
SWAV Shockwave Medical, Inc.
328.87
+0.10%
 
ABT Abbott Laboratories
106.89
-0.65%
 
BIO Bio-Rad Laboratories, Inc.
278.21
-2.48%
 
NARI Inari Medical, Inc.
38.18
+2.88%